Mumbai : Pharma Major Lupin Limited (Lupin) announced the launch of Abacavir and Lamivudine tablets, 600 mg/300 mg having received an approval from the United States Food and Drug Administration (FDA) earlier.
Lupin’s Abacavir and Lamivudine tablets, 600 mg/300 mg are the AB rated generic equivalent of ViiV Healthcare Company’s Epzicom tablets, 600 mg/300 mg. It is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection.
Epzicom tablets had US sales of USD 388.1 million (IMS MAT December 2016).
Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally. The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership position in the Anti-TB segment.